Compounded Semaglutide Is Ending for Most Patients: What to Do Next

For a while, compounded semaglutide became the practical workaround for patients who could not reliably get branded Ozempic or Wegovy. Shortages, high prices, and rapid telehealth expansion all pushed demand toward compounded products.

That landscape looks very different now.

As of May 8, 2026, the broad, shortage-era version of compounded semaglutide is fading fast. That does not mean every compounded product disappears overnight in every setting, but it does mean many patients should expect tighter access, more switching to FDA-approved brands, and more scrutiny around who can still receive a compounded version. Consult your healthcare provider before starting any medication.

Why compounded semaglutide grew so quickly

Compounding expanded during a period when branded semaglutide products were difficult to get. Under FDA rules, compounders can sometimes make versions of commercially available drugs when shortage conditions apply.

That mattered because:

• Wegovy and Ozempic demand surged
• many patients faced stockouts or delays
• branded treatment was often expensive without coverage
• telehealth platforms made access to compounded prescriptions much easier

For many patients, compounded semaglutide was not a first-choice product. It was the product they could actually get.

What changed legally and operationally

1) FDA said the semaglutide injection shortage was resolved

FDA states that the shortage of semaglutide injection products was resolved on February 21, 2025. That was a major turning point because shortage status had supported a large part of the compounding market.

Once shortage-based flexibility narrows, the legal and operational space for large-scale routine compounding also narrows.

2) FDA is taking a stricter position on bulk compounding

On April 30, 2026, FDA announced that it was proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances.

That does not instantly answer every edge case, but it clearly points in one direction: regulators are not treating broad routine compounding of these GLP-1 drugs as something they want to expand.

3) Major telehealth platforms have shifted toward branded access

Hims & Hers announced a strategic shift on March 9, 2026, saying it would no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and that existing patients would have the opportunity to transition to FDA-approved medicines when clinically appropriate.

Then on March 26, 2026, Hims & Hers announced that Novo Nordisk’s FDA-approved GLP-1 products were available to eligible customers through the platform.

That is an important nuance: the story is not simply “compounded semaglutide vanishes everywhere.” It is more accurate to say that broad mainstream access is being replaced by a branded-first model, with compounded access described as limited and case-specific where providers think it is clinically necessary.

Why this matters for patients

If you are currently using compounded semaglutide, the main issue is not just legality in the abstract. It is continuity.

You may run into:

• refill disruption
• product changes from your telehealth provider or pharmacy
• different concentration or device formats
• a need to convert to a branded pen or tablet
• different pricing than you expected

This is why it helps to make a plan before your next refill window rather than waiting until access changes suddenly.

Is compounded semaglutide safe?

Compounded semaglutide is not FDA-approved. That does not automatically mean every compounded product is unsafe, but it does mean the FDA approval framework for branded drugs does not apply in the same way.

FDA has separately warned about:

• dosing errors with compounded injectable semaglutide
• adverse events linked to compounded products
• quality concerns involving certain compounded versions
• confusion involving salt forms such as semaglutide sodium or acetate

For patients, the practical takeaway is simple: if you are using a compounded product, you should know exactly what formulation you are taking, how the dose is measured, and who is responsible for your follow-up plan.

What to do if you are currently taking compounded semaglutide

1) Talk to your prescriber before your supply runs low

Do not wait until the last dose. Ask:

• What exact product am I on now?
• What dose am I actually receiving each week?
• What FDA-approved alternative matches my current treatment goal?
• Would I need to restart at a lower dose when switching?

2) Confirm whether your next option is Wegovy, Ozempic, or another GLP-1

The right switch depends on why you are taking semaglutide:

• Wegovy is used for chronic weight management in eligible patients
• Ozempic is approved for type 2 diabetes, though some patients discuss other use cases with their clinician
• other GLP-1 or incretin options may be considered depending on your medical history and availability

3) Ask about current access routes, not just list price headlines

Novo Nordisk announced on February 24, 2026 that Wegovy, Ozempic, and Rybelsus will move to a $675 US list price on January 1, 2027. That matters, but it does not automatically tell you the cheapest option today.

Current access may depend on:

• insurance coverage
• deductibles or coinsurance
• manufacturer savings
• self-pay programmes such as NovoCare
• telehealth platform pricing and membership structure

4) Expect a transition period, not a perfect one-to-one swap

Many patients assume a switch from compounded to branded semaglutide is automatic. Often it is not.

Your clinician may decide to:

• restart titration more cautiously
• adjust the weekly dose
• monitor side effects again
• switch the delivery format
• document response before escalating further

That can feel frustrating, but it is often the safest way to avoid nausea, vomiting, or dosing confusion.

A practical switching checklist

Before you transition, try to have these details ready:

• the name of your current compounded product
• your current weekly dose and concentration
• your last dose date
• your refill date
• your side effects so far
• your weight trend or glucose trend if relevant
• your insurance and pharmacy details

That makes the switch conversation faster and safer.

Bottom line

As of May 8, 2026, the broad shortage-era market for compounded semaglutide is clearly shrinking. FDA has already said the semaglutide injection shortage was resolved, regulators are taking a stricter view of bulk compounding, and major telehealth platforms are moving patients toward FDA-approved branded products.

The most accurate takeaway is not that compounded semaglutide has disappeared in every possible scenario. It is that routine mainstream access is narrowing quickly, and patients should prepare for branded-first pathways unless their provider identifies a specific reason a compounded option is still needed.

If you are currently taking compounded semaglutide, make your transition plan before your next refill becomes a problem. Consult your healthcare provider before making any changes to your medication.

Related Articles

• Ozempic and Wegovy Price Drop in 2027: What It Means for Patients
• Wegovy Price and Availability
• What Is Obeda? Complete Guide

Sources

• FDA clarification on compounding as national GLP-1 supply began to stabilize: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
• FDA declaratory order on semaglutide injection shortage resolution (February 21, 2025): https://www.fda.gov/media/185526/download
• FDA press release, April 30, 2026, on proposed exclusion from the 503B bulks list: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
• FDA alert on dosing errors with compounded injectable semaglutide: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
• Hims & Hers strategic shift announcement, March 9, 2026: https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx
• Hims & Hers newsroom update on Wegovy and Ozempic availability, March 26, 2026: https://news.hims.com/newsroom/wegovy-r-pill-and-wegovy-r-pen-now-available-with-hims-hers
• Novo Nordisk list-price announcement, February 24, 2026: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504